About this trial
Patient Profile
participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery
Where’s this trial being run?
Bon Secours Cork, St Vincents University Hospital, and University Hospital Galway
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | MK-2870-012 |
|---|---|
| Number: | 24-58 |
| Full Title: | A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery |
| Principal Investigator: | Dr Janice Walsh |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Merck Sharp & Dohme LLC |
| Recruitment Started: |
Global: June 2024 Ireland: November 2024 |
| Global Recruitment Target: | 1530 |
|---|---|
| Ireland Recruitment Target: | 7 |